Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective validation study of KRAS status as a predictor of cetuximab response in metastatic colorectal cancer
2007-001949-18Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Tumor response by RECIST. Started Apr 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-001949-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001949-18.